Loading…

A randomized, double-blind, placebo-controlled pilot trial of low-intensity pulsed ultrasound therapy for refractory angina pectoris

Despite the advances in the treatment of cardiovascular diseases, effective treatment remains to be established to improve the quality of life and prognosis of patients with chronic coronary syndromes. This study was aimed to evaluate the effectiveness and safety of the low-intensity pulsed ultrasou...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2023-06, Vol.18 (6), p.e0287714-e0287714
Main Authors: Shindo, Tomohiko, Ito, Kenta, Ogata, Tsuyoshi, Kurosawa, Ryo, Eguchi, Kumiko, Kagaya, Yuta, Hanawa, Kenichiro, Hasebe, Yuhi, Nishimiya, Kensuke, Shiroto, Takashi, Takahashi, Jun, Okumura, Yasuo, Noguchi, Teruo, Ozaki, Yukio, Daida, Hiroyuki, Hagiwara, Nobuhisa, Masuyama, Tohru, Chikamori, Taishiro, Fukumoto, Yoshihiro, Tsujita, Kenichi, Kanai, Hiroshi, Yasuda, Satoshi, Shimokawa, Hiroaki
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the advances in the treatment of cardiovascular diseases, effective treatment remains to be established to improve the quality of life and prognosis of patients with chronic coronary syndromes. This study was aimed to evaluate the effectiveness and safety of the low-intensity pulsed ultrasound (LIPUS) therapy, which we have developed as a novel non-invasive angiogenic therapy through upregulation of endothelial nitric oxide synthase (eNOS). We conducted a randomized, double-blind, placebo-controlled (RCT) pilot trial of the LIPUS therapy for patients with refractory angina pectoris. The patients who received optimal medical therapy without indication of PCI or CABG due to the lack of graftability or complexity of coronary lesions were enrolled. They were randomly divided into the LIPUS treatment group (N = 31) and the placebo group (N = 25) in a 1:1 fashion. The LIPUS therapy was performed in a transthoracic manner for 20 min for 3 sections each (mitral, papillary muscle, and apex levels) under the conditions that we identified; frequency 1.875 MHz, intensity 0.25 MPa, and 32 cycles. The primary endpoint was weekly use of nitroglycerin. Secondary endpoints included stress myocardial perfusion imaging and others. The average weekly nitroglycerin use (times/week) was decreased from 5.50 to 2.44 in the LIPUS group and from 5.94 to 2.83 in the placebo group. The changes in the average weekly nitroglycerin use were comparable; -3.06 (95% CI: -4.481 to -1.648) in the LIPUS group (P
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0287714